Continuum Advisory LLC Purchases 13,544 Shares of Humana Inc. (NYSE:HUM)

Continuum Advisory LLC raised its position in shares of Humana Inc. (NYSE:HUM) by 19,917.6% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 13,612 shares of the insurance provider’s stock after purchasing an additional 13,544 shares during the quarter. Continuum Advisory LLC’s holdings in Humana were worth $4,311,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of HUM. LRI Investments LLC lifted its position in shares of Humana by 1,021.4% in the third quarter. LRI Investments LLC now owns 157 shares of the insurance provider’s stock valued at $50,000 after acquiring an additional 143 shares in the last quarter. Y Intercept Hong Kong Ltd boosted its stake in Humana by 180.7% in the 3rd quarter. Y Intercept Hong Kong Ltd now owns 5,741 shares of the insurance provider’s stock worth $1,818,000 after purchasing an additional 3,696 shares during the period. MML Investors Services LLC grew its holdings in Humana by 15.6% during the 3rd quarter. MML Investors Services LLC now owns 4,737 shares of the insurance provider’s stock valued at $1,500,000 after buying an additional 638 shares in the last quarter. XTX Topco Ltd bought a new stake in shares of Humana during the third quarter valued at approximately $1,727,000. Finally, National Bank of Canada FI lifted its holdings in shares of Humana by 54.4% in the third quarter. National Bank of Canada FI now owns 83,987 shares of the insurance provider’s stock worth $26,602,000 after buying an additional 29,593 shares in the last quarter. 92.38% of the stock is currently owned by institutional investors.

Humana Trading Down 0.5 %

HUM stock opened at $281.73 on Monday. The company has a market capitalization of $33.92 billion, a PE ratio of 24.95, a P/E/G ratio of 2.18 and a beta of 0.53. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.76 and a quick ratio of 1.76. Humana Inc. has a 12 month low of $213.31 and a 12 month high of $488.89. The firm’s 50-day moving average is $272.68 and its 200 day moving average is $326.83.

Humana (NYSE:HUM) last issued its earnings results on Wednesday, October 30th. The insurance provider reported $4.16 EPS for the quarter, topping analysts’ consensus estimates of $3.48 by $0.68. The business had revenue of $29.30 billion for the quarter, compared to analyst estimates of $28.66 billion. Humana had a net margin of 1.18% and a return on equity of 13.20%. On average, research analysts anticipate that Humana Inc. will post 16.14 EPS for the current year.

Humana Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be issued a $0.885 dividend. This represents a $3.54 annualized dividend and a dividend yield of 1.26%. The ex-dividend date is Tuesday, December 31st. Humana’s dividend payout ratio is 31.36%.

Wall Street Analyst Weigh In

Several research analysts have commented on HUM shares. JPMorgan Chase & Co. increased their price objective on shares of Humana from $332.00 to $396.00 and gave the company a “neutral” rating in a report on Wednesday, August 21st. Barclays raised their price target on Humana from $250.00 to $253.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. Royal Bank of Canada decreased their price objective on Humana from $400.00 to $265.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. UBS Group cut their target price on shares of Humana from $380.00 to $250.00 and set a “neutral” rating for the company in a report on Friday, October 4th. Finally, Deutsche Bank Aktiengesellschaft decreased their price target on shares of Humana from $349.00 to $250.00 and set a “hold” rating on the stock in a research note on Thursday, October 3rd. Twenty research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to data from MarketBeat, Humana has a consensus rating of “Hold” and a consensus price target of $315.86.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.